We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor.
Armenia, D., Di Carlo, D., Maffongelli, G., Borghi, V., Alteri, C., Forbici, F., et al. (2017). Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. HIV MEDICINE [10.1111/hiv.12388].
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens
Ceccherini-Silberstein, F;Andreoni, M;Perno, CF;Santoro, M
2017-01-01
Abstract
We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2017_Virological response and resistance profile in HIV1 infected patients starting darunavir-containing regimens HIV Med _armenia.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
588.78 kB
Formato
Adobe PDF
|
588.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
